secwatch.observer — SEC 8-K summary
======================================

Issuer:     COMPASS Pathways plc (CMPS)
CIK:        0001816590
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001628280-23-005357
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway
--------------------------------------------------------------------------------

- Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.
- Cash and cash equivalents fell to $143.2M at Dec 31, 2022 from $273.2M a year earlier.
- Phase 3 pivotal program for COMP360 psilocybin in TRD ongoing; top-line data from trial COMP 005 expected summer 2024.
- R&D expenses increased to $65.1M in FY2022 from $44.0M in FY2021, driven by clinical development.
- FY2023 net cash used in operating activities guided at $85M-$110M; Q1 2023 at $24M-$32M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/0001628280-23-005357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816590/000162828023005357/cmps-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-005357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer